- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
102 |
M. Dietzel et al. |
|
|
Table 6.1 Clinical manifestations of age-related macular degeneration
Early stage |
Focal drusen |
|
Irregular pigmentations of the retinal |
|
pigment epithelium including focal |
|
hyperpigmentations |
Late stage |
Detachment of the retinal pigment |
|
epithelium |
|
Tears in the retinal pigment epithelium |
|
Choroidal neovascularization |
|
Subretinal fibrosis |
|
Geographic atrophy of the retinal pigment |
|
epithelium |
Table 6.2 Probability of the development of advanced agerelated macular degeneration (AMD) with visual loss (in the presence of bilateral drusen in both eyes, in the presence of unilateral late-stage lesion in the fellow eye)
|
Risk of AMD with visual loss |
Initial findings |
(% per year) |
Bilateral drusen |
Approximately 1–5 |
Unilateral choroidal |
Approximately 7–12 |
neovascularization |
|
Unilateral foveal geographic |
Approximately 20–30 |
atrophy |
|
Unilateral retinal pigment |
Approximately 30–50 |
epithelium tear |
|
drusen |
|
|
|
|
|
|
choroidal |
|
|
|
|
detachment of |
|
|
|
the retinal |
||
neovascularization |
|
|
|
|
|
|
|
geographic |
|
pigment |
|
|
|
atrophy of the |
|
epithelium |
|
|
|
retinal pigment |
|
|
|
|
|
epithelium |
|
|
|
|
|
|
|
|
|
subretinal fibrosis
Fig. 6.1 Focal and diffuse drusen taking the form of abnormal material deposits between retinal pigment epithelium and Bruch’s membrane predispose to the development of late-stage atrophic or neovascular lesions of age-related macular degeneration associated with severe visual loss
20% of the patients who develop severe visual loss do so because of geographic atrophy – with an increasing tendency. Particularly for clinical studies, sophisticated systems of classification have been developed, which also include quantitative parameters such as the size of drusen (Age-Related Eye Disease Study Research Group [2]: ARED study classification; [3]: International Classification and Grading System for Age-Related Maculopathy and Age-Related Macular Degeneration; [4]: Rotterdam study classification).
6.2Drusen
The presence of specific drusen types indicates a risk of development of late-stage AMD (Fig. 6.1) [5–7]. Depending on the method of examination and definition, up to 80% of all patients over 60 years of age have evidence of drusen, usually in the macular and paramacular regions. At the same time,
drusen of Bruch’s membrane are not by any means a specific sign for AMD. However, as a common pathogenetic pathway, they occur in association with various acquired and genetically determined retinal and choroidal diseases.In AMD, drusen as hallmarks of disease are assumed to primarily develop on the genetic basis of risk polymorphisms in the complement factor H (CFH) gene. Several studies indicate an early influence of the CFH gene in the development of AMD and suggest a role in developing already early stages of AMD – in addition to the influence on the progression of more clinically relevant late stages of AMD [8]. The observation of diffuse deposits below the RPE [9] and vitronectin might be relevant to disease progression. Vitronectin is an extracellular matrix protein that is a major constituent of drusen [10] and an important inactivator of complement produced after complement stimulation by RPE cells [11] (see Chap. 5). In contrast, the AMD-associated risk variant in the ARMS2 gene appears to be more important in advanced forms of AMD and may support the formation of respectively the progression to late stages of AMD [12]. Thereby, the risk polymorphism in the ARMS2 gene appears to primarily influence the progression to exudative AMD rather than to geographic atrophy, while for the CFH risk variant, no differences in progression to different forms of late AMD have been shown [13]. This genetic predisposition for early AMD includes two aspects: The highly bilateral symmetry of drusen, comparable to a fingerprint, indicates a genetic basis of drusen development that goes beyond the association to genetic risk polymorphisms. Secondly, due to the genetic basis and the genetic identity of both eyes, there is an elevated risk of progression of early AMD to unilateral or bilateral late AMD (Table 6.2).
6 Early AMD |
103 |
|
|
In the absence of atrophy or exudative manifestation, patients with drusen usually have good visual function. However, detailed questioning may reveal functional deficits, such as abnormal dark adaptation or reading problems in dim light. The latter symptoms would not be detected by conventional tests of visual acuity. Other, more refined, psychophysical examinations allow both detection and quantification of such deficits [14, 15]. These include color-contrast vision deficits, blue-cone functions being the ones primarily affected [16]. These are relevant in daily life, since the ability to drive a car at night is impaired [17].
Various types of drusen can be distinguished on the basis of ophthalmoscopic, histological, and angiographic criteria classification of drusen:
6.2.1Classification of Drusen
•Hard (nodular) drusen
•Soft (exudative) drusen
•Basal linear deposits (diffuse drusen)
•Cuticular drusen (previous term: basal laminar drusen)
•Reticular pseudodrusen (reticular drusen, subretinal drusenoid deposits)
Different types of drusen can be present in the same
eye. While various characteristics suggest that the type
Fig. 6.2 Fundus photograph (a) with multiple hard drusen showing up as well-defined window defects owing to corresponding thinning of the retinal pigment epithelium (reduced content of intracellular melanin granules) seen on fluorescein angiography (b)
and distribution of drusen at the posterior pole can vary markedly between individuals, there is usually a high degree of symmetry between the two eyes of the same patient [18].
6.2.2Possible Spontaneous Modifications of Drusen
•Enlargement of hard drusen including progression of hard drusen to soft drusen (“drusen softening”)
•Detachment of the retinal pigment epithelium due to confluence of soft drusen
•Calcification
•Spontaneous regression
•Disappearance with subsequent corresponding atrophy
Hard drusen are usually <50 mm in diameter and
are seen as small, well-defined, yellowish deposits on ophthalmoscopy. Drusen of this type are associated with very little risk of progression to late-stage AMD with visual loss. Therefore, some authors interpreted such drusen as “normal” changes of aging (Fig. 6.2) [3]. However, findings in the Beaver Dam Eye Study indicate that the presence of a high number of hard drusen (more than eight) is associated with an increased risk of the occurrence of soft drusen or late-stage disease over a review period of 10 years [6].
104 |
M. Dietzel et al. |
|
|
Fig. 6.3 Soft drusen at
the posterior pole (a), which are hypofluorescent on fluorescein angiography (b)
Fig. 6.4 Cuticular drusen in a patient with a central pseudovitelliform macular
lesion, (a) fundus photograph and (b) fluorescein angiography
Soft drusen are larger and usually ill defined (Fig. 6.3). Soft drusen are associated with a higher risk of progression to late-stage AMD such as choroidal neovascularization. Ophthalmoscopic detection should prompt the ophthalmologist to advise regular central visual field testing with the Amsler grid. Soft drusen may enlarge over time to become confluent and cause detachments of the retinal pigment epithelium (“drusenoid retinal pigment epithelial detachment”). They may also disappear spontaneously; this
is usually associated with the development of corresponding atrophy of outer retinal layers.
Basal linear deposits are extensive deposits between the basal membrane of the RPE and the inner collagenous zone of Bruch’s membrane. Their diffuse occurrence can be readily identified only in histological sections. Clinically, they might be identified indirectly by choroidal perfusion analysis (see Sect. 6.4). Basal linear deposits are sometimes referred to as “diffuse drusen” because they primarily consist of
6 Early AMD |
105 |
|
|
a |
b |
c
Fig. 6.5 Reticular pseudodrusen (subretinal drusenoid deposits) on fundus photograph (a) and fundus autofluorescence image (b) in association with central geographic atrophy. This type of drusen is readily identified with confocal scanning laser ophthalmoscopy
and shows a uniform netlike structure. Using spectral domain optical coherence tomography (SD-OCT) techniques (c), corresponding hyperreflective changes are found above the cell layers of the RPE
membranous material that is similar to that found in soft drusen which are also located between the basal membrane of RPE and the inner collagenous zone of Bruch’s membrane [19].
Cuticular drusen are classified as a special variant of drusen, which usually occur in middle age and are associated with a relatively good prognosis [20]. They may be associated with a peculiar “vitelliform” lesion at the posterior pole (Fig. 6.4), i.e., accumulations of yellowish subretinal fluid in the macula. On angiographic examination, this type of drusen has a “stars-in-the- sky” appearance with myriads of small, equally sized, round hyperfluorescent window defects corresponding
to the stars. First, these drusen were histologically thought to represent nodular hyaline thickenings of the basal membrane of the RPE and were termed as basal laminar drusen [20]. After they were shown to contain the same constituents as soft drusen, they were renamed as cuticular drusen [21, 22].
Reticular pseudodrusen can, under certain conditions, be seen on fundus photography, but they are best visualized by confocal scanning laser ophthalmoscopy (cSLO) using near-infrared reflectance or autofluorescence imaging. They appear as uniform, small, netlike structures (Fig. 6.5). By using spectral domain optical coherence tomography (SD-OCT),
